Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs EmbraceRX

Embody
Graded #52

Higher grade

vs+17.9
EmbraceRX
Graded #363

Lower grade

The verdict

Embody takes it — 76.5/100 to 58.6/100.

Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbody +43
88
45
Dose & formulationEmbody +27
83
56
Clinical oversightEmbody +7
83
76
Labs & monitoringEmbody +2
54
52
FulfillmentEmbody +20
93
73
Contract termsEmbraceRX +30
25
55
Embody · left barEmbraceRX · right bar

The numbers

MetricEmbodyEmbraceRX
WeighScore76.5/10058.6/100
GradeCC
Scorecard rank#52#363
Semaglutide$79/mo (all doses, promotional rate, compounded)Not disclosed
Tirzepatide$129/mo (all doses, promotional rate, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Embody

Graded #52 · C

Strengths

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

Where it loses points

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
EmbraceRX

Graded #363 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard